In January, these pharmaceutical companies received subsidies, up to 120 million yuan!

[China Pharmaceutical network industry trends] the new year has begun In January, senior executives in the pharmaceutical industry announced their resignation, acquisition and merger Among them, Kunming Pharmaceutical, Zixin pharmaceutical, step pharmaceutical and other pharmaceutical companies received the news of subsidy funds On January 5, Cylon pharmaceutical announced that recently, Hunan Cylon pharmaceutical, a wholly-owned subsidiary of Cylon pharmaceutical, received two technical support funds of 7.6184 million yuan, accounting for 11.81% of the company's audited net profit attributable to shareholders of Listed Companies in 2017 From January 1, 2018 to the disclosure date of this announcement, the company and its subsidiaries received a total of 11.4824 million yuan of subsidies, accounting for 17.80% of the company's audited net profit attributable to shareholders of the listed company in 2017 The above subsidy funds will have a positive impact on the company's operating performance in 2018, and the total profit is expected to increase by 11.4824 million yuan Kunming Pharmaceutical Group announced on January 5 that it had issued the announcement on obtaining government subsidies on January 3, 2019 From the content of the announcement, Kunming Pharmaceutical Group and its subsidiaries received about 80.24 million yuan of subsidies from January 1 to January 3, 2018, including 34.15 million yuan of subsidies related to assets and 46.09 million yuan of subsidies related to income The company expects that the amount included in other income is 42834700 yuan, which is expected to increase the current net profit by 36.0495 million yuan, accounting for 10.75% of 2017 net profit (335.2868 million yuan) Zixin Pharmaceutical Co., Ltd announced on January 4 that, according to relevant regulations, the company's subsidiary caoxiadan Pharmaceutical Co., Ltd recently received a subsidy of 4.012 million yuan for discount interest projects As of the date of this announcement, the subsidy funds have been received The subsidy is related to the company's daily activities, and the financial support funds are sporadic There is uncertainty about whether it will continue to occur in the future Step Pharma announced on January 3 that recently, the company and its subsidiaries within the scope of consolidated statements received subsidies of RMB 121 million (Unaudited) Among them, 800000 yuan has been officially approved by relevant departments but not yet received, and 67810000 yuan has been received but not yet formally approved by relevant departments Whether it can be recognized that there is uncertainty in the current profit and loss and the impact on the company's net profit in 2018 cannot be accurately predicted The rest of the government subsidies related to income are directly included in the current profit and loss, which will have a certain impact on the company's net profit in 2018 On January 3, Ningbo minoua Pharmaceutical Co., Ltd announced that from April 27, 2017 to December 29, 2018, Ningbo minoua Pharmaceutical Co., Ltd and its subsidiaries received a total of 4.5259 million yuan of income related subsidies, accounting for 10.13% of the company's recent audited net profit The company will include all the above subsidies into the current profit and loss, and it is expected to have a certain positive impact on the company's net profit in 2018 after deducting relevant taxes Haizheng Pharmaceutical Co., Ltd announced on January 3 that the company has participated in the national science and technology major special project of "research and development of new varieties of emergency medical drugs and their key innovation technology system", in which the subsidiary task "industrialization emergency production of emergency McAb drugs" undertaken by the company received a subsidy of 3.821 million yuan, which will be allocated in 2018, 2019 and 2020 On January 2, the company obtained the first subsidy of 1.8277 million yuan, which was included in the "deferred income" subject, and included in the "other income" subject in future periods according to the project development progress Sanlian Pharmaceutical Co., Ltd on January 2, Harbin Sanlian Pharmaceutical Co., Ltd announced that the company and its wholly-owned subsidiary lanxiha Sanlian Pharmaceutical Co., Ltd received a total of about 1838700 yuan of subsidy funds from November 23, 2018 to December 31, 2018 The above subsidy funds will have a positive impact on the company's operating performance in 2018, and the total profit is expected to increase by 18.38 million yuan.